Couple of days ago FDA approved a new molecule, ribociclib , when used in combination with an aromatase inhibitor, letrozole in HR+/HER- advanced or metastatic breast cancer showed promising results. This article provides an overview of this clinical trial and some of the noted adverse events observed. Very recently FDA approved a new molecule, ribociclib, for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- (HR+/HER-) negative advanced or metastatic breast cancer.
Ribociclib, a CDK4/6 inhibitor in combination with an aromatase inhibitor (letrozole) has shown promising results compared to letrozole alone, and hence can be used as initial endocrine-based therapy. Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drug which help slow the cancer progression by prohibiting two proteins called…
